Clinical

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.

The top news out of the annual meeting of the American Society of Clinical Oncology (ASCO) highlighted findings in gliobastoma, HER2-low breast cancer, and Hodgkin lymphoma.

The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).

Implantable cardioverter defibrillators (ICDs) were found to have a beneficial effect on mortality in patients with chronic kidney disease (CKD).

Jorge Larranaga, MD, discusses the AURORA 2 study and its emphasis on voclosporin.

Belimumab and voclosporin are highlighted as key contributors to the lupus nephritis treatment landscape.

Although the skin condition is common in systemic lupus erythematosus (SLE), it usually is not the initial manifestation.

Jaime Murillo, MD, discusses the impact of diabetes on cardiovascular disease.

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, leads a discussion surrouding early intervention in the management of type 2 diabetes.

Addressing cancer patients' lack of housing or food insecurity affects care outcomes, but how can the Center for Medicare and Medicaid Innovation build this into a reward structure?

Abstracts presented at the annual meeting of the American College of Rheumatology (ACR) show 2 tocilizumab biosimilars were comparable to the reference product.

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies.

Cutting the amount of Monthly Enhanced Oncology Services payments and limiting qualifying tumor types will curtail revenue to practices. But after the financial results in the Oncology Care Model, that's by design.

Unlike the Oncology Care Model, the Enhancing Oncology Model will focus on 7 common cancer types, which experts say offers advantages and disadvantages for practices.

The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.

Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.

Results from the ALPINE trial were presented Tuesday at a late-breaking session of the 64th American Society of Hematology Annual Meeting and Exposition, held in New Orleans, Louisiana.

David Lieberman, MD, PhD, discusses the results of the phase 3 LAVENDER trial of trofinetide and the phase 3 AVATAR trial of blarcamesine and how patients and families can learn about eligible clinical trials for possible participation.

An expert provides an overview of the RSBQ and CGI score measurement tools and other tools/methods of assessment used in clinical practice.

A multicenter study supports the use of ruxolitinib in steroid-refractory and steroid-dependent chronic graft-versus-host disease, adding to promising clinical trial findings.

Authors of the observational cohort study developed and validated novel sex-informed prognostic and genomic scoring systems for patients with myelodysplastic syndrome (MDS).

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

The report is the first recorded case of acute respiratory distress syndrome (ARDS) that required venovenous extracorporeal membrane oxygenation and was complicated by spontaneous spleen rupture.

Key opinion leaders emphasize the significant role of immunotherapy for patients being treated for gastroesophageal cancer.

Expert panelists navigate optimal treatment strategies for patients with gastroesophageal cancer.

Key social determinants of health impacting MDD are discussed by expert payer panelists.

Drs Chitre and Weaver explore social and health care disparities more prominently affecting various MDD patient populations.

Results from a phase 3 study of patients with acute myeloid leukemia (AML) are being presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses.